Abstract
Elderly patients with acute myeloid leukemia (AML) are difficult to treat due to higher proportion of high risk factors and the efficacy of conventional chemotherapy remains unsatisfying. In recent years, researches concerning risk stratification of elderly patients with AML have prompted the individualization of therapeutic approaches. Besides, the advent of hypomethylating agents(HMA), novel targeted drugs, immunotherapy and the improvement of hematopoietic stem cell transplantation (HSCT) have shown promising prospects in elevating remission and survival rates while lowering treatment-related toxicities, thus providing new orientations of the diagnosis and treatment of this special population. This article reviews literatures of progress in the treatment of elderly patients with AML in aspects of stratified evaluation, chemotherapy, HMA, molecular targeted therapy, immunotherapy, cyclin kinase inhibitors, HSCT, and so on. Key words: Leukemia, myeloid, acute; Aged; Geriatric assessment; Demethylation; Molecular targeted therapy; Immunotherapy; Hematopoietic stem cell transplantation
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
